Rush University Medical Center

Running trials

• Not yet recruiting

  A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

  NCT07728188· Phase 3· AbbVie· Source

• Not yet recruiting

  The Study of Brave-LC LDN Treatment Trial

  NCT07916259· Phase 3· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Not yet recruiting

  Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy

  NCT07795593· Phase 4· University of Michigan· Source

• Not yet recruiting

  Synovial Fluid Withdrawal or PRP Injection For Acute ACL Tears and Cytokines

  NCT07142369· Rush University Medical Center· Source

• Recruiting

  Pridopidine Phase 3 Study in Huntington's Disease

  NCT07609108· Phase 3· Prilenia· Source

• Not yet recruiting

  RUSH Food is Medicine Veggie Rx - GusNIP Produce Prescription

  NCT07376044· Rush University Medical Center· Source

• Recruiting

  PRImary Care Strategies for Weight Management (PRISM) Study

  NCT07288294· Rush University Medical Center· Source

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

  NCT07483073· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

  NCT07483099· Phase 2· Eli Lilly and Company· Source

• Recruiting

  U.S. Prospective Evaluation of EPIONE Device for Percutaneous MSK Procedures

  NCT07325578· Precision IO Group· Source

• Recruiting

  ROAM OA: Functional and Patient Reported Outcomes Wearing a Knee Brace for Unicompartmental OA

  NCT07224958· Rush University Medical Center· Source

• Recruiting

  LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

  NCT07415044· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

  NCT07326709· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT07154290· Phase 2· Regeneron Pharmaceuticals· Source

• Recruiting

  Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

  NCT07473778· Gilead Sciences· Source

• Recruiting

  Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis

  NCT07339111· Phase 3· Medipost, Inc.· Source

• Recruiting

  Mobilizing Community Hypertension Access Pilot

  NCT07547345· Rush University Medical Center· Source

• Recruiting

  CREO - Microwave Ablation Feasibility Study

  NCT07817147· Banner Health· Source

• Recruiting

  Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

  NCT07059091· Phase 2· Johns Hopkins University· Source

• Recruiting

  Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

  NCT07195591· Phase 3· GT Medical Technologies, Inc.· Source

• Recruiting

  Social Cognition Training in Individuals With Huntington's Disease

  NCT06828471· Rush University Medical Center· Source

• Recruiting

  Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

  NCT07100080· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· Phase 3· Eli Lilly and Company· Source

• Recruiting

  An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07184996· Phase 3· Sanofi· Source

• Recruiting

  An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  NCT07184931· Phase 3· Sanofi· Source

• Recruiting

  Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  NCT06982521· Phase 3· Relay Therapeutics, Inc.· Source

• Recruiting

  COPD Resources, Education, and Activity Designed for You Study

  NCT07125053· Rush University Medical Center· Source

• Recruiting

  Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

  NCT07029581· Phase 2· ACADIA Pharmaceuticals Inc.· Source

• Recruiting

  Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR

  NCT06790784· Phase 3· Jaeb Center for Health Research· Source

• Recruiting

  Inspire UAS High Apnea Hypopnea Index (AHI)/High Body Mass Index (BMI) Post-Approval Study

  NCT07113288· Inspire Medical Systems, Inc.· Source

• Recruiting

  RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

  NCT07002034· Phase 2· Reunion Neuroscience Inc· Source

• Recruiting

  Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  NCT06937086· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  NCT06937099· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

  NCT06846281· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

  NCT06944522· Phase 3· BlueRock Therapeutics· Source

• Recruiting

  Rapid Evacuation and Access of Cerebral Hemorrhage Trial

  NCT06870812· Emory University· Source

• Recruiting

  Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

  NCT06952660· Phase 4· Pfizer· Source

• Recruiting

  Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  NCT06881784· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  The Dragon PLC Trial (DRAGON-PLC)

  NCT06914648· Maastricht University· Source

• Recruiting

  Thrombectomy Using Pulsed Aspiration for Reperfusion of Brain Occlusions

  NCT06029491· RapidPulse, Inc· Source

• Active, not recruiting

  Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss

  NCT06734273· Early phase 1· Nicholas Skertich· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

  NCT06742996· Phase 3· BeOne Medicines· Source

• Recruiting

  Preventative Screening and Health Coaching in a Food Insecure Population

  NCT06907524· Rush University Medical Center· Source

• Recruiting

  MOTION Clinical Trial

  NCT06843980· Moximed· Source

• Recruiting

  E3 Hypertension - A Team-based, Multidisciplinary Model in Addressing Barriers to Hypertension Control

  NCT06899750· Rush University Medical Center· Source

• Active, not recruiting

  A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

  NCT06709014· Phase 3· Annovis Bio Inc.· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

  NCT06548360· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  Evaluate the Safety and Effectiveness of the Polymotion Hip Resurfacing (PHR) System Compared to Total Hip Arthroplasty

  NCT06792539· JointMedica Inc.· Source

• Active, not recruiting

  Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

  NCT06700343· Phase 3· Amgen· Source

Showing 50 of 203.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Osteoarthritis6 recruiting
• Crohn's disease5 recruiting
• Lung cancer5 recruiting
• Obesity5 recruiting
• Stroke5 recruiting
• Ulcerative colitis5 recruiting
• High blood pressure4 recruiting
• Huntington's disease4 recruiting
• Liver and biliary tract cancer4 recruiting
• Parkinson disease4 recruiting
• Atrial fibrillation3 recruiting
• Metastatic breast cancer3 recruiting
• Acute myeloid leukaemia2 recruiting
• Aortic stenosis2 recruiting
• Cervical cancer2 recruiting
• Childhood cancers2 recruiting
• Chronic kidney disease2 recruiting
• COPD2 recruiting
• Depression2 recruiting
• Haemophilia2 recruiting
• Heart failure2 recruiting
• HIV2 recruiting
• Multiple myeloma2 recruiting
• Multiple sclerosis2 recruiting
• Osteoporosis2 recruiting
• Ovarian cancer2 recruiting
• Peripheral artery disease2 recruiting
• Sarcoma2 recruiting
• Ventricular tachycardia2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• ALS (motor neurone disease)1 recruiting
• Alzheimer disease1 recruiting
• Aplastic anaemia1 recruiting
• Autism1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Diabetic eye disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Dystonia1 recruiting
• Epilepsy1 recruiting
• Essential tremor1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Glioblastoma1 recruiting
• Hodgkin lymphoma1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Kidney cancer1 recruiting
• Lewy body dementia1 recruiting
• Liver cirrhosis1 recruiting
• Long COVID and ME/CFS1 recruiting
• Mantle cell lymphoma1 recruiting
• Obstructive sleep apnoea1 recruiting
• Pancreatic cancer1 recruiting
• Prostate cancer1 recruiting
• Sickle cell disease1 recruiting
• Thalassaemia1 recruiting
• Triple-negative breast cancer1 recruiting
• Type 2 diabetes1 recruiting
• Vitiligo1 recruiting

Closed trials

• Withdrawn

  A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer

  NCT06229392· Phase 1· Rush University Medical Center· Source

• Completed

  Use of Bedside Imaging and Community Health Workers for Early Screening and Referral of Pre-symptomatic Stage B Heart Failure in the Emergency Department

  NCT06769880· Rush University Medical Center· Source

• Withdrawn

  A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease

  NCT07011771· Phase 1/2· Capsida Biotherapeutics, Inc.· Source

• Completed

  Probiotic Use for Recovery Enhancement From Long COVID-19

  NCT06643299· Phase 2· Rush University Medical Center· Source

• Terminated

  Study of the Oral Treatment MTR-601 in Cervical Dystonia

  NCT06830642· Phase 2· Motric Bio· Source

• Completed

  Preventing Medication Mismanagement in People Living With Dementia Through Automated Medication Dispensing With Facial Recognition and Video Observation

  NCT06691256· Phase 2· HiDO Technologies· Source

• Completed

  RECOVER-SLEEP: Platform Protocol

  NCT06404086· Phase 2· Duke University· Source

• Completed

  RECOVER-ENERGIZE Platform Protocol

  NCT06404047· Duke University· Source

• Completed

  RECOVER-AUTONOMIC Platform Protocol

  NCT06305780· Phase 2· Kanecia Obie Zimmerman· Source

• Completed

  Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study

  NCT06234488· Medical College of Wisconsin· Source

• Completed

  A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAF

  NCT06144632· Biosense Webster, Inc.· Source

• Completed

  Novartis - Closing the Gap in Cardiovascular Risk: Engage, Empower, Evaluate

  NCT06027905· Rush University Medical Center· Source

• Completed

  A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee

  NCT06000410· Phase 3· Organogenesis· Source

• Completed

  RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms

  NCT05965752· Duke University· Source

• Completed

  RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms

  NCT05595369· Phase 2· Kanecia Obie Zimmerman· Source

• Completed

  A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)

  NCT05878938· Phase 3· Novo Nordisk A/S· Source

• Completed

  Aquacel Hypersensitivity Dressing in TJAs

  NCT06011629· Phase 4· Rush University Medical Center· Source

• Completed

  Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

  NCT05819359· Phase 2· Bial R&D Investments, S.A.· Source

• Completed

  Testing Feasibility of Medication Adherence Problem Solving for Hypertension

  NCT05630521· Rush University Medical Center· Source

• Recruiting

  PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

  NCT05313165· LimFlow, Inc.· Source

• Terminated

  Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer

  NCT04936230· Phase 2· National Cancer Institute (NCI)· Source

• Terminated

  A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)

  NCT05574010· Phase 1/2· Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA· Source

• Completed

  Engaging Men From Blue-collar Industries in Weight Loss

  NCT05386238· Rush University Medical Center· Source

• Completed

  Memesto Wearable Device for Persons With Dementia

  NCT05153161· Phase 1· Edgewater Safety Systems, Inc.· Source

• Completed

  Prophylaxis Regimen for Hemophilia A Patients

  NCT05036278· Phase 4· Bayer· Source

• Completed

  Research Study Investigating How Well NDec Works in People With Sickle Cell Disease

  NCT05405114· Phase 2· Novo Nordisk A/S· Source

• Completed

  Study of ATH434 in Participants with Multiple System Atrophy

  NCT05109091· Phase 2· Alterity Therapeutics· Source

• Terminated

  EvaLuate EndoVascular Treatment of Acutely Ruptured Shallow Intradural Aneurysms With the Pipeline™ Flex Embolization Device With Shield TEchnology™ (ELEVATE)

  NCT04391803· Medtronic Neurovascular Clinical Affairs· Source

• Completed

  A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

  NCT05348785· Phase 2· Biogen· Source

• Completed

  Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue

  NCT04972097· Angiodynamics, Inc.· Source

• Terminated

  Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

  NCT05169437· Phase 2· Tempus AI· Source

• Completed

  Studying Heart Ablation After Left Atrial Closure in High-Bleeding-Risk Atrial Fibrillation Patients

  NCT07580937· University of Chicago· Source

• Completed

  A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors

  NCT05053139· Phase 3· Novo Nordisk A/S· Source

• Completed

  Disrupt PAD BTK II Study With the Shockwave Peripheral IVL System

  NCT05007925· Shockwave Medical, Inc.· Source

• Recruiting

  (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

  NCT04996875· Phase 2· Cogent Biosciences, Inc.· Source

• Completed

  Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation

  NCT05130268· Phase 4· American Heart Association· Source

• Completed

  A Study of SEA-CD40 Given With Other Drugs in Cancers

  NCT04993677· Phase 2· Seagen Inc.· Source

• Completed

  A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

  NCT04935879· Phase 3· Pfizer· Source

• Terminated

  Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

  NCT04588246· Phase 3· NRG Oncology· Source

• Completed

  The Impact of Circadian Misalignment on Colonic Barrier Homeostasis in Ulcerative Colitis

  NCT05180279· Rush University Medical Center· Source

• Completed

  A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)

  NCT04299464· Phase 2· Hoffmann-La Roche· Source

• Completed

  An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD

  NCT04770545· Phase 3· Apellis Pharmaceuticals, Inc.· Source

• Completed

  Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

  NCT04750226· Phase 3· AbbVie· Source

• Terminated

  Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy

  NCT04676386· Addario Lung Cancer Medical Institute· Source

• Completed

  A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

  NCT03776071· Phase 3· Denovo Biopharma LLC· Source

• Completed

  Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

  NCT04562766· Phase 3· Principia Biopharma, a Sanofi Company· Source

• Completed

  Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee

  NCT04636229· Phase 3· Organogenesis· Source

• Completed

  Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

  NCT04471844· NovoCure Ltd.· Source

• Completed

  LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma

  NCT04577807· Phase 2· Istari Oncology, Inc.· Source

• Completed

  A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

  NCT04599855· Phase 4· Janssen Research & Development, LLC· Source

Showing 50 of 128.

Conditions

Diseases this institution publishes on or runs trials for.

• Alzheimer disease262 works · 11 trials
• Osteoarthritis93 works · 16 trials
• Parkinson disease75 works · 16 trials
• Obstructive sleep apnoea19 works · 2 trials
• Haemophilia11 works · 10 trials
• Fibromyalgia10 works · 0 trials
• Hidradenitis suppurativa6 works · 0 trials
• Vascular dementia5 works · 1 trial
• Lewy body dementia4 works · 2 trials
• Multiple system atrophy4 works · 3 trials
• Trigeminal neuralgia3 works · 0 trials
• Essential tremor3 works · 1 trial